A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

AIDS-Related Opportunistic Infections / blood Antitubercular Agents / administration & dosage Area Under Curve Dose-Response Relationship, Drug Drug Combinations HIV Infections / blood Humans Tuberculosis / blood

Journal

Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 9 11 2018
medline: 20 8 2020
entrez: 9 11 2018
Statut: ppublish

Résumé

Contrasting findings have been published regarding the effect of human immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). The aim of this systematic review was to investigate the effect of HIV infection on the PK of the first-line TB drugs (FLDs) rifampicin, isoniazid, pyrazinamide and ethambutol by assessing all published literature. Searches were performed in MEDLINE (through PubMed) and EMBASE to find original studies evaluating the effect of HIV infection on the PK of FLDs. The included studies were assessed for bias and clinical relevance. PK data were extracted to provide insight into the difference of FLD PK between HIV-positive and HIV-negative TB patients. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and its protocol was registered at PROSPERO (registration number CRD42017067250). Overall, 27 studies were eligible for inclusion. The available studies provide a heterogeneous dataset from which consistent results could not be obtained. In both HIV-positive and HIV-negative TB groups, rifampicin (13 of 15) and ethambutol (4 of 8) peak concentration (C HIV infection may be one of several factors that reduce FLD exposure. We could not make general recommendations with respect to the role of dosing. There is a need for consistent and homogeneous studies to be conducted.

Identifiants

DOI: 10.1007/s40262-018-0716-8 PMID: 30406475 PMC: PMC7019645
pubmed: 30406475
doi: 10.1007/s40262-018-0716-8
pii: 10.1007/s40262-018-0716-8
pmc: PMC7019645
doi:

Substances chimiques

Antitubercular Agents 0
Drug Combinations 0

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

747-766

Subventions

Organisme : Medical Research Council
ID : MC_U117588499
Pays : United Kingdom

Références

Chest. 2001 Nov;120(5):1520-4
pubmed: 11713129
Antimicrob Agents Chemother. 2002 Aug;46(8):2358-64
pubmed: 12121905
Drugs. 2002;62(15):2169-83
pubmed: 12381217
Antimicrob Agents Chemother. 2003 Jul;47(7):2118-24
pubmed: 12821456
Clin Infect Dis. 2004 Jan 15;38(2):280-3
pubmed: 14699462
Clin Infect Dis. 2004 Feb 15;38(4):556-64
pubmed: 14765350
Clin Pharmacokinet. 2004;43(6):395-404
pubmed: 15086276
Antimicrob Agents Chemother. 2004 Nov;48(11):4473-5
pubmed: 15504887
Clin Infect Dis. 2005 May 15;40(10):1481-91
pubmed: 15844071
Arch Dis Child. 2005 Jun;90(6):614-8
pubmed: 15908628
Clin Infect Dis. 2005 Dec 1;41(11):1638-47
pubmed: 16267738
Antimicrob Agents Chemother. 2006 Feb;50(2):407-13
pubmed: 16436690
Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7
pubmed: 16569826
Antimicrob Agents Chemother. 2007 Jul;51(7):2329-36
pubmed: 17438043
Antimicrob Agents Chemother. 2007 Nov;51(11):3781-8
pubmed: 17724157
Clin Infect Dis. 2008 Nov 15;47(10):1339-44
pubmed: 18922070
BMC Med. 2009 Apr 22;7:19
pubmed: 19386087
Clin Infect Dis. 2009 Jun 15;48(12):1685-94
pubmed: 19432554
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Clin Infect Dis. 2010 May 15;50 Suppl 3:S201-7
pubmed: 20397949
Lancet Infect Dis. 2010 Jul;10(7):455-63
pubmed: 20610327
Antimicrob Agents Chemother. 2010 Oct;54(10):4192-200
pubmed: 20660695
Clin Infect Dis. 2011 May;52(9):e194-9
pubmed: 21467012
Antimicrob Agents Chemother. 2011 Sep;55(9):4230-7
pubmed: 21690284
Antimicrob Agents Chemother. 2011 Sep;55(9):4122-7
pubmed: 21709081
J Infect Dis. 2011 Dec 15;204(12):1951-9
pubmed: 22021624
Antimicrob Agents Chemother. 2012 May;56(5):2357-63
pubmed: 22330931
Antimicrob Agents Chemother. 2012 Jun;56(6):3232-8
pubmed: 22411614
J Infect Dis. 2012 Jun;205(11):1765-6; author reply 1766
pubmed: 22459734
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):813-23
pubmed: 24597717
Talanta. 2014 Apr;121:9-17
pubmed: 24607103
Antimicrob Agents Chemother. 2014 Jun;58(6):3468-74
pubmed: 24709267
Clin Pharmacokinet. 2014 Jun;53(6):489-507
pubmed: 24777631
Drugs. 2014 Jun;74(8):839-54
pubmed: 24846578
Ther Drug Monit. 2015 Feb;37(1):22-32
pubmed: 24943062
Antimicrob Agents Chemother. 2014 Dec;58(12):7164-70
pubmed: 25224007
Antimicrob Agents Chemother. 2015 Feb;59(2):1162-7
pubmed: 25487804
J Antimicrob Chemother. 2015 Apr;70(4):1115-23
pubmed: 25505005
Eur Respir J. 2015 Feb;45(2):569-71
pubmed: 25653274
Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65
pubmed: 25654354
BMC Infect Dis. 2015 Mar 14;15:126
pubmed: 25887748
Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13
pubmed: 26055359
Antimicrob Agents Chemother. 2015 Oct;59(10):6175-80
pubmed: 26248378
J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365
pubmed: 26407268
PLoS One. 2015 Oct 26;10(10):e0141002
pubmed: 26501782
J Antimicrob Chemother. 2016 Mar;71(3):703-10
pubmed: 26661397
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9
pubmed: 26810651
Pediatr Infect Dis J. 2016 May;35(5):530-4
pubmed: 26825153
Expert Opin Drug Metab Toxicol. 2016 May;12(5):509-21
pubmed: 26950189
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9
pubmed: 27480859
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195
pubmed: 27516382
Expert Rev Clin Pharmacol. 2017 Jan;10(1):47-58
pubmed: 27724114
Clin Infect Dis. 2017 Jan 1;64(1):104-105
pubmed: 27789609
PLoS One. 2016 Nov 10;11(11):e0166030
pubmed: 27832142
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855070
Microbiol Spectr. 2017 Jan;5(1):
pubmed: 28084209
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28289033
N Engl J Med. 1989 Mar 2;320(9):545-50
pubmed: 2915665
N Engl J Med. 2018 Aug 30;379(9):823-833
pubmed: 30157391
Am J Respir Crit Care Med. 1995 Jan;151(1):129-35
pubmed: 7812542
Ann Pharmacother. 1996 Sep;30(9):919-25
pubmed: 8876848
Am J Respir Crit Care Med. 1997 May;155(5):1717-22
pubmed: 9154882
Clin Infect Dis. 1997 Jul;25(1):104-11
pubmed: 9243044
Ann Intern Med. 1997 Aug 15;127(4):289-93
pubmed: 9265429
Antimicrob Agents Chemother. 1997 Dec;41(12):2670-9
pubmed: 9420037
J Med Assoc Thai. 1998 Jan;81(1):25-8
pubmed: 9470318
Int J Tuberc Lung Dis. 1998 Aug;2(8):670-5
pubmed: 9712282

Auteurs

Alper Daskapan (A)

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

Lusiana R Idrus (LR)

Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

Maarten J Postma (MJ)

Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Bob Wilffert (B)

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

Jos G W Kosterink (JGW)

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

Ymkje Stienstra (Y)

Department of Internal Medicine-Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Daniel J Touw (DJ)

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.
Unit of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

Aase B Andersen (AB)

Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.

Adrie Bekker (A)

Department of Paediatrics and Child Health, University of Stellenbosch, Cape Town, South Africa.

Paolo Denti (P)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Agibothu K Hemanth Kumar (AK)

National Institute for Research in Tuberculosis (ICMR), Chennai, India.

Kidola Jeremiah (K)

National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, Tanzania.

Awewura Kwara (A)

College of Medicine and Emerging Pathogens Institutes, University of Florida, Gainesville, FL, USA.

Helen McIlleron (H)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Graeme Meintjes (G)

Institute of Infectious Diseases and Molecular Medicine, Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.

Joep J van Oosterhout (JJ)

Dignitas International, Zomba, Malawi.
Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi.

Geetha Ramachandran (G)

National Institute for Research in Tuberculosis (ICMR), Chennai, India.

Neesha Rockwood (N)

Institute of Infectious Diseases and Molecular Medicine, Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
Department of Medicine, Imperial College London, London, UK.

Robert J Wilkinson (RJ)

Institute of Infectious Diseases and Molecular Medicine, Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, South Africa.
Department of Medicine, Imperial College London, London, UK.
The Francis Crick Institute, London, UK.

Tjip S van der Werf (TS)

Department of Internal Medicine-Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Jan-Willem C Alffenaar (JC)

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands. j.w.c.alffenaar@umcg.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Infections opportunistes liées au SIDA › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Aire sous la courbe › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Relation dose-effet des médicaments › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Préparations pharmaceutiques › Association médicamenteuse › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Systematic Review on the Effect of HIV...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › A Systematic Review on the Effect of HIV...